Best Life Sciences Companies in Michigan, United States

Developer of renal denervation for treatment of hypertension. The company has developed a catheter-based approach for the delivery of diagnostic and therapeutic agents into the area surrounding the peripheral blood vessels. The Peregrine renal denervation system is being evaluated for treating hypertension.

HistoSonics is developing Histotripsy technology, licensed from the University of Michigan. It is a non-invasive, image guided therapeutic ultrasound system that excises tissue. Uses pulsed sound waves to induce cavitation that mechanically destroys tissue, tumors and plaque at the cellular level. Application areas include cardiovascular, oncology, neurology and urology.

Funding rounds

• Oct 2025Series E$250M
• Jul 2024Series D$102M
• Dec 2022Series D$85M
• Nov 2020Conventional Debt$15M

Founders & team

Mike BluePresident and CEO

Investors

Yonjin Capital, Varian Medical Systems, Johnson & Johnson Innovation, Lumira Ventures, Venture Investors, SWIB (State of Wisconsin Investment Board)

Tech stack

AccessibeAdobe Experience Platform LaunchCivicthemeCloudflareCloudflare Bot ManagementCore-Js

Developer of therapeutics to treat liver and metabolic diseases. The company's lead product is MSDC-0602K, a second-generation insulin sensitizer for the treatment of NASH. It has the potential to reduce metabolic dysregulation that insulin resistance and tissue damage.

Developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders. It focuses on discovering and developing targeted, novel regenerative therapeutics. The company's pipeline includes synaptogenic treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s disease, Fragile X Syndrome, MS, Parkinsons, Traumatic Brain Injury, Stroke, and Autism Spectrum Disorders. It leverages Bryostatin-1 and its analogues for therapeutic development.

Funding rounds

• Jun 2025Post IPO$5.5M
• Sep 2024Post IPO$3.2M
• Nov 2022Post IPO$15M
• Jun 2021Post IPO$12.5M

Founders & team

Alan TuchmanCEO

Investors

Fraxa, Alpha Capital, American Capital Management, Ellis International, Empery Asset Management, Belzberg

Provider of total shoulder replacement solutions based on glenoid technology. It offers InSet Total Shoulder System for shoulder arthroplasty, and InSet PLUS augmented glenoid which has cortical support to the implant around the perimeter that shields the implant from rocking and loosening forces during daily shoulder motion activities.

Funding rounds

• Jul 2025Series E$40M
• Mar 2025Series E$20.1M
• Aug 2023Venture Debt$45M
• Feb 2023Series D$42M

Founders & team

Stephen GuntherFounderRob BallChief Executive OfficerMatt AhearnCOO

Investors

Michigan Angel Fund, Accelerate Michigan, Gilde Healthcare, USVP, Lightstone Ventures, Gilmartin Capital

Tech stack

AstraCloudflareCore-JsElementorFont AwesomeFullcalendar

High-performance imaging spectrometers revolutionizing gamma-ray source identification and localization. The company specializes in advanced radiation detection technology, offering solutions for nuclear power, CBRNE defense, waste management, safeguards, medical applications, and environmental monitoring. They provide imaging spectrometers, spectrometers, handheld directional RIIDs, and custom systems. Their cutting-edge CZT technology enables fast startup, compact design, industry-leading energy resolution, efficient imaging, and a user-friendly interface. They focus on customer needs, offering complete solutions for identifying, quantifying, and localizing sources. Their products are used in nuclear power plants and by emergency responders worldwide. They offer hardware and software solutions, including SourceTerm RMS. The company's technology supports various applications, including nuclear power plant contamination cleanup, CBRNE response, environmental monitoring, defense, and medical imaging.

Funding rounds

• Dec 2025Grant (prize money)$1.4M
• Jul 2024Grant (prize money)$206.5K
• Jun 2022Grant (prize money)$1.4M
• Jun 2021Grant (prize money)$1.4M

Founders & team

Weiyi WangResearch And Development Director

Investors

OSTI, Oriza Ventures

Tech stack

UbuntuYoutubeNginxGoogle AnalyticsSectigo

Provider of prosthetic rehabilitation solutions after limb loss, with a focus on neuromuscular interfaces and robotic technology. It is designed to detect voluntary nerve and muscle control signals to facilitate naturalistic function of upper limb prosthetics. It consists of implantable intramuscular electrodes, a sensing unit, a socket mounted receiver, and software for controlling the system

Funding rounds

• Feb 2026Series A$5M

Founders & team

Alex VaskovCo-Founder & CTOTod BortonChief Executive Officer

Investors

Otto Bock

Preclinical CRO driving smarter drug development with integrated services and scientific clarity. Focused on helping pharmaceutical, biotech, and academic teams advance early drug candidates. They offer integrated support across formulation development, bioanalysis, PK/ADME, toxicology, drug delivery technologies, and strategic consulting. Services are customized to meet timelines and therapeutic needs. They provide tailored approaches to improve solubility, enhance stability, and meet delivery requirements. High-sensitivity drug quantification using HPLC and LC-MS/MS is used for pharmacokinetic, safety, and toxicology studies. Planning and guidance are offered to close knowledge gaps, align with regulatory needs, and support clear decision-making. Studies are designed to assess how compounds are absorbed, distributed, metabolized, and eliminated, along with early insights into toxicology. Support is available for novel delivery systems including MAP technology. They combine scientific insight with practical experience to help move programs forward, guided by collaboration, transparency, and a strong track record in early development.

Funding rounds

• May 2025Grant (prize money)$1.6M
• Mar 2025Grant (prize money)$299.6K
• Mar 2025Grant (prize money)$6M
• Aug 2023Grant (prize money)$1.3M

Founders & team

Elke LipkaPresident and CEO

Investors

HHS, MassChallenge

Tech stack

AngularCore-JsGoogle AnalyticsGoogle Font ApiHstsMicrosoft 365

Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms. The company focuses on next-generation precision oncology, developing predictive diagnostic tools for cancer treatment. They offer innovative solutions like Antibody-drug Conjugate Treatment Response Scores and Immunotherapy Response Score, utilizing proprietary calculation methods and algorithms. These tools aim to predict patient response to therapies, ensuring individuals receive the most effective treatment. The company's approach combines tumor biology and microenvironment analysis, incorporating factors like tumor mutation burden and protein expression. They strive to accelerate the impact of precision medicine, offering advanced algorithmic biomarkers for antibody drug conjugates and immunotherapy. The company is committed to improving cancer care through scientific innovation and data-driven decision-making. This is a B2B, SaaS, and tech company in the healthcare sector.

Funding rounds

• Nov 2024Series C$6.1M
• Jul 2021Series C$90M
• Nov 2020Series B$5M
• May 2018Series B$26M

Founders & team

Scott TomlinsCo-FounderDan RhodesCo-Founder & CEO

Investors

Arboretum Ventures, Baird Capital, eLab Ventures, Wellington, Monashee Investment Management, HIGHSIDE Global

ONL Therapeutics is a developer of small peptide molecules to prevent the death of photoreceptor cells. It is developing therapies for eye-related disorders using its technology. Its technology is focused on preventing the death of key retinal cells, including photoreceptors which are the root cause of vision loss and the leading cause of blindness. Its lead product ONL-1204 is a small molecule peptide which inhibits the Fas pathway that induces apoptosis. Its preclinical in-vivo data claims to have supported the potential application in retinal detachment, age-related macular degeneration (AMD) and other chronic retinal diseases.

Provider of a technology platform for cell sorting. The company offers a microbubble cell separation platform by using Cell Separation and Buoyancy Activated Cell Sorting (BACS) technology which is used in purifying cells from blood and tissues for research or diagnostics areas.

Funding rounds

• Apr 2025Series C$20M
• May 2023Series B$6M
• Oct 2021Series B$17.5M
• Dec 2019Series A—

Founders & team

Brandon McNaughtonChief Executive Officer & Co-Founder

Investors

Berkeley Catalyst Fund, University of Michigan, Invest Detroit, eLab Ventures, Genoa Ventures, Invest Michigan

Tech stack

BootstrapCart FunctionalityCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookie Notice

Developer of a medical device to treat severely calcified arterial disease. The company develops pulsatile intravascular lithotripsy (PIVL), a therapy device that is delivered through a balloon-based platform called PULSE IVL System to restore blood flow to blockages in the legs caused by severe calcium buildup.

Funding rounds

• Oct 2024Series B$36M
• Apr 2023Series B$8.8M
• Jan 2023Series B$20M
• Oct 2022Series A$4.4M

Founders & team

Robert ChisenaCo-Founder & CTOMark TolandCEO

Investors

BioStar Capital, Cue Growth Partners, Corewell Health Ventures

Tech stack

CloudflareCloudflare Bot ManagementGenerateblocksGodaddyGoogle AnalyticsGoogle Font Api